NewAmsterdam Pharma Company
D

NAMS

20.175
USD
0.24
(1.18%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
66,029
الربح لكل سهم
-2
العائد الربحي
-
P/E
-12
حجم السوق
2,419,587,710

العنوان: NewAmsterdam Pharma Company NV

القطاع: الرعاية الصحية
الصناعة: Biotechnology
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

أسئلة شائعة حول سهم NewAmsterdam Pharma Company